Phase II Trial of Postoperative Radiotherapy and Panitumumab in High-risk Salivary Gland Malignancies.
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 01 Feb 2016
At a glance
- Drugs Panitumumab (Primary)
- Indications Salivary gland cancer
- Focus Biomarker; Therapeutic Use
- 14 Jul 2012 This trial was reinitiated (see related profile 220147).
- 13 Jun 2011 Planned end date changed from 1 Nov 2014 to 1 Nov 2015 as reported by ClinicalTrials.gov.
- 13 Jun 2011 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.